In-vivo activation of Raf-1 inhibits tumor growth and development in a xenograft model of human medullary thyroid cancer

Anti-Cancer Drugs

Volumn 17, Issue 7, 2006, Pages 849-853

  Vaccaro, Abram ^a   Chen, Herbert ^a   Kunnimalaiyaan, Muthusamy ^a,b  

^a UNIVERSITY OF WISCONSIN   (United States)

^b University of Wisconsin Health   (United States)

Author keywords

Chromogranin A; Medullary thyroid cancer; Neuroendocrine tumor; raf 1; Thyroid cancer; Xenograft model

Indexed keywords

CALCITONIN; ESTRADIOL; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; RAF PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; DATA ANALYSIS; ENZYME ACTIVATION; IN VITRO STUDY; MALE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; THYROID MEDULLARY CARCINOMA; TUMOR VOLUME; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CHROMOGRANIN A; ENZYME ACTIVATION; HUMANS; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEUROSECRETORY SYSTEMS; PROTO-ONCOGENE PROTEINS C-RAF; THYROID NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS;

EID: 33748132208     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cad.0000217424.36961.47     Document Type: Article

References (17)

1. Chen H, Kunnimalaiyaan M, Van Gompel JJ. Medullary thyroid cancer: the functions of raf-1 and human achaete-scute homologue-1. Thyroid 2005; I5:511-521.
2. Chen H, Roberts JR, Ball DW, Eisele DW, Baylin SB, Udelsman R, Bulkley GB. Effective long-term palliation of symptomatic, incurable metastatic medullary thyroid cancer by operative resection. Ann Surg 1998; 227:887-895.
3. Kunnimalaiyaan M, Chen H. Raf-1 pathway: a molecular target for treatment of select neuroendocrine tumors? Anticancer Drugs 2006; 17:139-142.
4. Park JI, Strock CJ, Ball DW, Nelkin BD. The Ras/Raf/MEK/extracellular signal-regulated kinase pathway induces autocrine-paracrine growth inhibition via the leukemia inhibitory factor/JAK/STAT pathway. Mol Cell Biol 2003; 23:543-554.
5. Van Gompel JJ, Kunnimalaiyaan M, Holen K, Chen H. ZM336372, a Raf-1 activator, suppresses growth and neuroendocrine hormone levels in carcinoid tumor cells. Mol Cancer Ther 2005; 4:910-917.
6. Chen H, Biel MA, Borges MW, Thiagalingam A, Nelkin BD, Baylin SB, Ball DW. Tissue-specific expression of human achaete-scute homologue-1 in neuroendocrine tumors: transcriptional regulation by dual inhibitory regions. Cell Growth Differ 1997; 8:677-686.
7. Chen H, Carson-Walter EB, Baylin SB, Nelkin BD, Ball DW. Differentiation of medullary thyroid cancer by C-Raf-1 silences expression of the neural transcription factor human achaete-scute homolog-1. Surgery 1996; 120:168-172.
8. Sippel RS, Carpenter JE, Kunnimalaiyaan M, Chen H. The role of human achaete-scute homolog-1 in medullary thyroid cancer cells. Surgery 2003; 134:866-871.
9. McMahon M. Steroid receptor fusion proteins for conditional activation of Raf-MEK-ERK signaling pathway. Methods Enzymol 2001; 332:401-417.
10. Kunnimalaiyaan M, Traeger K, Chen H. Conservation of the Notch1 signaling pathway in gastrointestinal carcinoid cells. Am J Physiol Gastrointest Liver Physiol 2005; 289:G636-G642.
11. Sippel RS, Carpenter JE, Kunnimalaiyaan M, Lagerholm S, Chen H. Raf-1 activation suppresses neuroendocrine marker and hormone levels in human gastrointestinal carcinoid cells. Am J Physiol Gastrointest Liver Physiol 2003; 285:G245-G254.
12. Carson EB, McMahon M, Baylin SB, Nelkin BD. Ret gene silencing is associated with Raf-1-induced medullary thyroid carcinoma cell differentiation. Cancer Res 1995; 55:2048-2052.
13. Carson-Walter EB, Smith DP, Ponder BA, Baylin SB, Nelkin BD. Post-transcriptional silencing of RET occurs, but is not required, during raf-1 mediated differentiation of medullary thyroid carcinoma cells. Oncogene 1998; 17:367-376.
14. Ezzat S, Huang P, Dackiw A, Asa SL. Dual inhibition of RET and FGFR4 restrains medullary thyroid cancer cell growth. Clin Cancer Res 2005; 11:1336-1341.
15. Strock CJ, Park JI, Rosen DM, Ruggeri B, Denmeade SR, Ball DW, Nelkin BD. Activity of irinotecan and the tyrosine kinase inhibitor cep-751 in medullary thyroid cancer. J Clin Endocrinol Metab 2006; 91:79-84.
16. Musunuru S, Carpenter JE, Sippel RS, Kunnimalaiyaan M, Chen H. A mouse model of carcinoid syndrome and heart disease. J Surg Res 2005; 126:102-105.
17. Nakaya M, Tachibana H, Yamada K. Effect of estrogens on the interferon-gamma producing cell population of mouse splenocytes. Biosci Biotechnol Biochem 2006; 70:47-53.